Printed from https://ideas.repec.org/s/spr/eujhec.html
Content
June 2025, Volume 26, Issue 4
- 537-540 Pricing combination products: not how but who?
by Adrian Towse & Andrew Briggs & Lotte Steuten - 541-560 Does implementing opt-out solve the organ shortage problem? Evidence from a synthetic control approach
by Selina Schulze Spuentrup - 561-575 Strategic behavior and entry deterrence by branded drug firms: the case of authorized generic drugs
by Lu Yao & Mengde Liu - 577-588 Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports
by Yan Li & Yanqiu Chen & Jize Sun & Mingyu Jiang & Aixia Ma & Tiantian Tao & Pingyu Chen - 589-604 Comparison of four approaches in eliciting health state utilities with SF-6Dv2
by Hosein Ameri & Thomas G. Poder - 605-617 The societal cost of ‘unwanted’ loneliness in Spain
by Bruno Casal & Eva Rodríguez-Miguez & Berta Rivera - 619-625 Assessing a decade of leukaemia-related premature mortality costs: impact on productivity loss in Spain
by Josep Darbà & Meritxell Ascanio & Ainoa Agüera - 627-639 Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases
by Ákos Szabó & Valentin Brodszky & Fanni Rencz - 641-651 Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market
by Ramsis R. Croes & Frederik T. Schut & Marco Varkevisser - 653-670 Benefits beyond health in the willingness to pay for a quality-adjusted life-year
by Linda M. Vries & Werner B. F. Brouwer & Pieter H. M. Baal - 671-682 Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma
by Richard Huan Xu & Zuyi Zhao & Tianxin Pan & Andrea Monteiro & Hongfei Gu & Dong Dong - 683-696 Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
by Evert A. Manders & Sibren den Berg & Saco J. Visser & Carla E. M. Hollak
April 2025, Volume 26, Issue 3
- 337-351 Psychometric validation of the Chinese versions of EQ-5D-Y-3L and the experimental EQ-TIPS in children and adolescents with COVID-19
by Wenjing Zhou & Yaqin Li & Jan Busschbach & Michael Herdman & Zhihao Yang & Yanming Lu - 353-361 The formal care costs of dementia: a longitudinal study using Swedish register data
by Jennifer Zilling & Ulf-G. Gerdtham & Johan Jarl & Sanjib Saha & Sofie Persson - 363-375 A critical review of the use of R2 in risk equalization research
by Wynand P. M. M. Ven & Richard C. Kleef - 377-402 Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis
by Vilaplana-Prieto C & Oliva-Moreno J - 403-411 Testing four cognition bolt-on items to the EQ-5D in a general Chinese population
by Meixia Liao & Hongyan Wu & Zhihao Yang & Yan Huang & Mathieu F. Janssen & Gouke Bonsel & Nan Luo - 413-425 Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens
by Sara W. Quist & Sophie te Dorsthorst & Roel D. Freriks & Maarten J. Postma & Carel B. Hoyng & Freekje Asten - 427-454 Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial
by Paddy Gillespie & Frank Moriarty & Susan M. Smith & Anna Hobbins & Sharon Walsh & Barbara Clyne & Fiona Boland & Tara McEnteggart & Michelle Flood & Emma Wallace & Caroline McCarthy - 455-471 Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade
by Lotte Westerink & Sharon Wolters & Guiling Zhou & Arjan Postma & Cornelis Boersma & Job Frank Martien Boven & Maarten Jacobus Postma - 473-485 The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease
by M. Mercédesz Angyal & Mathieu F. Janssen & Péter L. Lakatos & Valentin Brodszky & Fanni Rencz - 487-501 Valuation of the EQ-5D-3L in Jordan
by Abeer Rabayah & Bram Roudijk & Fredrick Dermawan Purba & Fanni Rencz & Saad Jaddoua & Uwe Siebert - 503-512 Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis
by Michael Abbott & Mandy Ryan & Rodolfo Hernández & Lynda McKenzie & Sebastian Heidenreich & Lynne Hocking & Caroline Clark & Morad Ansari & David Moore & Anne Lampe & Ruth McGowan & Jonathan Berg & Zosia Miedzybrodzka - 513-536 An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries
by Giovanny Leon & Christophe Carbonel & Aparajit Rampuria & Ravindra Singh Rajpoot & Parth Joshi & Panos Kanavos
March 2025, Volume 26, Issue 2
- 147-151 Setting incentives right with long-term risk adjustment
by Simon Reif & Sabrina Schubert & Achim Wambach - 153-182 Long-term returns to local health-care spending
by Jakub Červený & Jan C. van Ours - 183-198 Monetary value of health—a practical decision-making framework combining equity considerations and WTP
by Elizabeta Ribarić & Ismar Velić & Ana Bobinac - 199-222 Workload and short sickness absences in a cohort of Finnish hospital employees
by Tero Kuusi & Martti Kulvik & Mikko Härmä & Annina Ropponen - 223-231 Population normative data for OxCAP-MH capability scores
by Péter György Balázs & Agata Łaszewska & Judit Simon & Valentin Brodszky - 233-241 Does medial tourism promote growth in healthcare sector?
by Hassan F. Gholipour & Kourosh Esfandiar - 243-265 The hidden cost of sophistication: economic complexity and obesity
by Ronald Djeunankan & Sosson Tadadjeu & Henri Njangang & Ummad Mazhar - 267-273 A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial
by Etienne Minvielle & Henri Leleu & Marc Masseti & Arlindo Ferreira & Gérard Pouvourville & Mario Di Palma & Florian Scotté - 275-297 The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol
by Henry Bailey & Bram Roudijk & Ricky Brathwaite - 299-311 Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico
by Omar Galárraga & Marta Wilson-Barthes & Carlos Chivardi & Nathalie Gras-Allain & Fernando Alarid-Escudero & Monica Gandhi & Kenneth H. Mayer & Don Operario - 313-323 Migration-related determinants of health-care service utilization among persons with a direct migration background in Germany: an exploratory study based on the German Socio-Economic Panel (SOEP)
by Thomas Grochtdreis & Hans-Helmut König & Judith Dams - 325-335 Economies of scope in the Norwegian public hospital sector
by Nils Arne Lindaas & Kjartan Sarheim Anthun & Sverre A. C. Kittelsen & Jon Magnussen
February 2025, Volume 26, Issue 1
- 1-5 Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?
by Livio Garattini & Giovanni Fattore - 7-21 The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events
by Cate Bailey & Kim Dalziel & Leanne Constable & Nancy J. Devlin & Harriet Hiscock & Helen Skouteris & Tessa Peasgood - 23-34 Economic evaluation of intensive home treatment in comparison to care as usual alongside a randomised controlled trial
by Ansam Barakat & Jurgen E. Cornelis & Jack J. M. Dekker & Nick M. Lommerse & Aartjan T. F. Beekman & Matthijs Blankers - 35-48 Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden
by Thomas Sejersen & Sophie Graham & Anne-Berit Ekström & Anna-Karin Kroksmark & Marta Kwiatkowska & Michael L. Ganz & Nahila Justo & Karl Gertow & Alex Simpson - 49-62 Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system
by Silvia Fenix-Caballero & Adrián Sanchez-Vegas & Emilio Jesús Alegre Del-Rey & David Epstein & Leticia Garcia-Mochon & Antonio Olry de Labry Lima - 63-70 Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation
by Clara Mukuria & Matthew Franklin & Sebastian Hinde - 71-85 The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries
by Hamraz Mokri & Pieter Baal & Maureen Rutten-van Mölken - 87-93 Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes
by Maiken Skovrider Aaskoven & Trine Kjær & Dorte Gyrd-Hansen - 95-115 Do institutions matter for citizens’ health status? Empirical evidence from Italy
by M. Alessandra Antonelli & Giorgia Marini - 117-128 Costs associated with insufficient physical activity in Germany: cross-sectional results from the baseline examination of the German national cohort (NAKO)
by Sophie Gottschalk & Hans-Helmut König & Andrea Weber & Michael F. Leitzmann & Michael J. Stein & Annette Peters & Claudia Flexeder & Lilian Krist & Stefan N. Willich & Katharina Nimptsch & Tobias Pischon & Sylvia Gastell & Karen Steindorf & Florian Herbolsheimer & Nina Ebert & Karin B. Michels & Anja Dorrn & Volker Harth & Nadia Obi & André Karch & Henning Teismann & Henry Völzke & Claudia Meinke-Franze & Leon Klimeck & Teresa L. Seum & Judith Dams - 129-139 Cost-effectiveness analysis of procalcitonin and lung ultrasonography guided antibiotic prescriptions in primary care
by Giulio Cisco & Armando N. Meier & Nicolas Senn & Yolanda Mueller & Andreas Kronenberg & Isabella Locatelli & José Knüsli & Loïc Lhopitallier & Noemie Boillat-Blanco & Joachim Marti - 141-142 Letter to the Editor: Lazzaro responds to Kennedy et al
by Carlo Lazzaro - 143-146 Correction: AOTMiT reimbursement recommendations compared to other HTA agencies
by Aneta Mela & Dorota Lis & Elżbieta Rdzanek & Janusz Jaroszyński & Marzena Furtak-Niczyporuk & Bartłomiej Drop & Tomasz Blicharski & Maciej Niewada
December 2024, Volume 25, Issue 9
- 1471-1484 Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China
by Aixue Zhang & Jing Li & Zhuxin Mao & Zitong Wang & Jing Wu & Nan Luo & Peng Liu & Pei Wang - 1485-1504 What remains after the money ends? Evidence on whether admission reductions continued following the largest health and social care integration programme in England
by Vasudha Wattal & Katherine Checkland & Matt Sutton & Marcello Morciano - 1505-1515 Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease
by Richard Huan Xu & Nan Luo & Dong Dong - 1517-1527 The causal effect of early retirement on medication use across sex and occupation: evidence from Danish administrative data
by Jolien Cremers & Torben Heien Nielsen & Claus Thorn Ekstrøm - 1529-1537 Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study
by Timothée Lehut & Céline Lambert & Romain Mortier & Emmanuel Futier & Russell Chabanne & Ulrich Bauer & Philippe Verdier & Ramin Ravan & Philippe Ocquidant & Charline Mourgues & Alexandre Lautrette - 1539-1555 The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands
by Micha J. Pilz & Simon Seyringer & Lára R. Hallsson & Andrew Bottomley & Femke Jansen & Madeleine T. King & Richard Norman & Marianne J. Rutten & Irma M. Verdonck-de Leeuw & Peter D. Siersema & Eva Maria Gamper - 1557-1567 Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands
by Simon Pol & Maarten J. Postma & Cornelis Boersma - 1569-1580 Economic value of diastasis repair with the use of mesh compared to no intervention in Italy
by Carla Rognoni & Alessandro Carrara & Micaela Piccoli & Vincenzo Trapani & Nereo Vettoretto & Giorgio Soliani & Rosanna Tarricone - 1581-1594 From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands
by Iris Meulman & Ellen Uiters & Mariëlle Cloin & Jeroen Struijs & Johan Polder & Niek Stadhouders - 1595-1603 Costs attributable to hypercholesterolemia in a single period and over the life cycle
by Stephanie Reitzinger & Miriam Reiss & Thomas Czypionka - 1605-1624 Poverty, work intensity, and disability: evidence from European countries
by Chiara Mussida & Dario Sciulli - 1625-1640 Comparing GPs according to their model of practice: are multiprofessional group practices associated with more favourable working conditions?
by Myriam Biais & Matthieu Cassou & Carine Franc
November 2024, Volume 25, Issue 8
- 1291-1310 AOTMiT reimbursement recommendations compared to other HTA agencies
by Aneta Mela & Dorota Lis & Elżbieta Rdzanek & Janusz Jaroszyński & Marzena Furtak-Niczyporuk & Bartłomiej Drop & Tomasz Blicharski & Maciej Niewada - 1311-1331 The Economic Costs of Informal Care: Estimates from a National Cross-Sectional Survey in The Netherlands
by Saif Elayan & Viola Angelini & Erik Buskens & Alice Boer - 1333-1343 A Spanish value set for the SF-6D based on the SF-12 v1
by Jorge-Eduardo Martínez-Pérez & José-María Abellán-Perpiñán & Fernando-Ignacio Sánchez-Martínez & Juan-José Ruiz-López - 1345-1360 Comparing heuristic valuation processes between health state valuation from child and adult perspectives
by Stefan A. Lipman & Vivian T. Reckers-Droog - 1361-1370 Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers
by Wenjing Zhou & Anle Shen & Zhihao Yang & Pei Wang & Bin Wu & Michael Herdman & Jan Busschbach & Nan Luo - 1371-1381 Unravelling risk selection in Spanish general government employee mutual funds: evidence from cancer hospitalizations in the public health network
by Jaime Pinilla & Beatriz G. López-Valcárcel & Enrique Bernal-Delgado - 1383-1391 Measuring EQ-5D-5L utility values in parents who have experienced perinatal death
by Elizabeth M. Camacho & Katherine J. Gold & Margaret Murphy & Claire Storey & Alexander E. P. Heazell - 1393-1416 A principled approach to non-discrimination in cost-effectiveness
by Darius N. Lakdawalla & Jason N. Doctor - 1417-1435 Systematic methodological review of health state values in glaucoma cost-utility analyses
by Kevin Kennedy & Gurkaran Sarohia & Dominik Podbielski & Simon Pickard & Jean-Eric Tarride & Feng Xie - 1437-1448 Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)
by Louis S. Matza & Katie D. Stewart & Marie Fournier & Donna Rowen & Robin Lachmann & Maurizio Scarpa & Eugen Mengel & Travis Obermeyer & Evren Ayik & Fernando Laredo & Ruth Pulikottil-Jacob - 1449-1459 The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands
by Vivian Reckers-Droog & Joost Enzing & Werner Brouwer - 1461-1469 Preference-based utility weights for the Individualized Neuromuscular Quality of Life Questionnaire (INQoL), with a focus on non-dystrophic myotonia (NDM)
by Andrew Lloyd & Kim Rand & Cleo Pike & Crispin Ellis
September 2024, Volume 25, Issue 7
- 1087-1094 Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states
by Zhihao Yang & Kim Rand & Elly Stolk & Jan Busschbach & Nan Luo - 1095-1115 Impact of Long COVID on productivity and informal caregiving
by Joseph Kwon & Ruairidh Milne & Clare Rayner & Román Rocha Lawrence & Jordan Mullard & Ghazala Mir & Brendan Delaney & Manoj Sivan & Stavros Petrou - 1117-1131 Risk adjustment for regional healthcare funding allocations with ensemble methods: an empirical study and interpretation
by Tuukka Holster & Shaoxiong Ji & Pekka Marttinen - 1133-1146 Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK
by J. P. Sevilla & Daniel Tortorice & David Kantor & John Regan & Kinga H. Meszaros & Ekkehard C. Beck & Najida Begum & David E. Bloom - 1147-1163 The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands
by Ghyli Kirshner & Peter Makai & Chiara Brouns & Lonneke Timmers & Ron Kemp - 1165-1176 Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people
by Tracey H. Sach & Mary Onoja & Holly Clarke & Miriam Santer & Ingrid Muller & Taeko Becque & Beth Stuart & Julie Hooper & Mary Steele & Sylvia Wilczynska & Matthew J. Ridd & Amanda Roberts & Amina Ahmed & Lucy Yardley & Paul Little & Kate Greenwell & Katy Sivyer & Jacqui Nuttall & Gareth Griffiths & Sandra Lawton & Sinéad M. Langan & Laura Howells & Paul Leighton & Hywel C. Williams & Kim S. Thomas - 1177-1204 Looking inside the lab: a systematic literature review of economic experiments in health service provision
by Massimo Finocchiaro Castro & Calogero Guccio & Domenica Romeo - 1205-1215 A state-level analysis of macro-level factors associated with hospital readmissions
by Reginald A. Silver & Joumana Haidar & Chandrika Johnson - 1217-1238 Can redistribution of vaccine improve global welfare? Lessons from COVID-19
by Gunjan Kumari & Oindrila Dey - 1239-1260 On spillovers in economic evaluations: definition, mapping review and research agenda
by María J. Mendoza-Jiménez & Job Exel & Werner Brouwer - 1261-1273 Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis
by Andrea Marcellusi & Francesco Saverio Mennini & Massimo Andreoni & Loreta A. Kondili - 1275-1289 Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions
by Susanna Sten-Gahmberg & Kine Pedersen & Ingrid Gaarder Harsheim & Hanna Isabel Løyland & Øyvind Snilsberg & Tor Iversen & Geir Godager & Erik Magnus Sæther & Birgit Abelsen
August 2024, Volume 25, Issue 6
- 915-924 Valuation of EQ-5D-5L health states from cancer patients’ perspective: a feasibility study
by Qingqing Chai & Zhihao Yang & Xiaoyan Liu & Di An & Jiangyang Du & Xiumei Ma & Kim Rand & Bin Wu & Nan Luo - 925-934 The economic burden of mental disorders: results from the Netherlands mental health survey and incidence study-2
by B. F. M. Wijnen & M. Have & R. Graaf & H. J. Hoek & J. Lokkerbol & Filip Smit - 935-950 How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe
by Anna-Maria Fontrier & Bregtje Kamphuis & Panos Kanavos - 951-962 New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?
by Chi Shen & Qiwei Deng & Sha Lai & Liu Yang & Dantong Zhao & Yaxin Zhao & Zhongliang Zhou - 963-977 Healthcare information management and operational cost performance: empirical evidence
by Amit S. Malhan & Kiarash Sadeghi-R & Robert Pavur & Lou Pelton - 979-997 Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
by Daniel Tobias Michaeli & Thomas Michaeli & Sebastian Albers & Tobias Boch & Julia Caroline Michaeli - 999-1011 Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders
by Mario Cesare Nurchis & Francesca Clementina Radio & Luca Salmasi & Aurora Heidar Alizadeh & Gian Marco Raspolini & Gerardo Altamura & Marco Tartaglia & Bruno Dallapiccola & Gianfranco Damiani - 1013-1030 Country-level effects of diagnosis-related groups: evidence from Germany’s comprehensive reform of hospital payments
by Robert Messerle & Jonas Schreyögg - 1031-1039 Patient-reported experience is associated with higher future revenue and lower costs of hospitals
by Alice Giese & Rasheda Khanam & Son Nghiem & Thomas Rosemann & Michael M. Havranek - 1041-1055 Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication
by Jen-Yu Amy Chang & Chien-Ning Hsu & Juan Manuel Ramos-Goñi & Nan Luo & Hsiang-Wen Lin & Fang-Ju Lin - 1057-1070 Projected costs of informal care for older people in England
by Bo Hu & Javiera Cartagena-Farias & Nicola Brimblecombe & Shari Jadoolal & Raphael Wittenberg - 1071-1085 The elicitation of patient and physician preferences for calculating consumer-based composite measures on hospital report cards: results of two discrete choice experiments
by Martin Emmert & Stefan Rohrbacher & Florian Meier & Laura Heppe & Cordula Drach & Anja Schindler & Uwe Sander & Christiane Patzelt & Cornelia Frömke & Oliver Schöffski & Michael Lauerer
July 2024, Volume 25, Issue 5
- 731-741 Length of hospital stays and financial incentives: evidence from Dutch rehabilitation centers
by Katalin Gaspar & Ramsis Croes & Misja Mikkers & Xander Koolman - 743-762 The impacts of working from home on individual health and well-being
by Manuel Denzer & Philipp Grunau - 763-774 Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis
by Lorna Wills & Diana Nagarwalla & Clare Pearson & Sean McPhail & Rose Hinchliffe & Ben Sharpless & Fahmina Fardus-Reid & Lyndsy Ambler & Samantha Harrison & Jon Shelton - 775-785 Losses of lifetime employment duration and productivity for patients with different subtypes and stages of lung cancer
by Szu-Chun Yang & Wu-Wei Lai & Tzu-I. Wu & Jing-Shiang Hwang & Jung-Der Wang & Fuhmei Wang - 787-811 Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec
by Christian R. C. Kouakou & Jie He & Thomas G. Poder - 813-828 How do family doctors respond to reduced waiting times for cancer diagnosis in secondary care?
by Helen Hayes & Rachel Meacock & Jonathan Stokes & Matt Sutton - 829-844 A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe
by Li Sun & Shruti Patel & Camilla Fiorina & Audrey Glass & Lise Rochaix & Anna M. Foss & Rosa Legood - 845-855 Assessing the relation between financial performance and long-term bank loan interest rates for healthcare providers in the Netherlands: a panel data analysis
by Erik Wackers & Rick Smit & Niek Stadhouders & Patrick Jeurissen - 857-876 Pay-for-Performance incentives for specialised services in England: a mixed methods evaluation
by Yan Feng & Søren Rud Kristensen & Paula Lorgelly & Rachel Meacock & Alberto Núñez-Elvira & Marina Rodés-Sánchez & Luigi Siciliani & Matt Sutton - 877-888 Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose
by Maria Katharina Schweitzer & Manuel Nico Dold & Astrid Genet & Klaus Gossens & Thomas Klein-Hessling & Nils Löffler & Matthias Rabel & Andrej Rasch & Eva-Maria Reuter & Jessica Schmelcher & Natalia Wolfram & Sebastian Werner - 889-901 The EORTC QLU-C10D: the Hong Kong valuation study
by Richard Huan Xu & Eliza Lai-yi Wong & Nan Luo & Richard Norman & Jens Lehmann & Bernhard Holzner & Madeleine T. King & Georg Kemmler - 903-913 Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice experiment
by Saskia Schawo & Renske Hoefman & Vivian Reckers-Droog & Liesbet Lawerman-van de Wetering & Yifrah Kaminer & Werner Brouwer & Leona Hakkaart-van Roijen
June 2024, Volume 25, Issue 4
- 549-562 Psychometric properties and general population reference values for PROMIS Global Health in Hungary
by Alex Bató & Valentin Brodszky & Ariel Zoltán Mitev & Balázs Jenei & Fanni Rencz - 563-578 Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemic
by Sebastian Himmler & Job Exel & Werner Brouwer & Sebastian Neumann-Böhme & Iryna Sabat & Jonas Schreyögg & Tom Stargardt & Pedro Pita Barros & Aleksandra Torbica - 579-600 Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study
by Vivienne Hillerich & Frederik Valbert & Silke Neusser & Oliver Pfaar & Ludger Klimek & Annette Sperl & Thomas Werfel & Eckard Hamelmann & Cordula Riederer & Stefanie Wobbe-Ribinski & Anja Neumann & Jürgen Wasem & Janine Biermann-Stallwitz - 601-613 The effect of duration and time preference on the gap between adult and child health state valuations in time trade-off
by Zhongyu Lang & Arthur E. Attema & Stefan A. Lipman - 615-629 The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial
by Dirk Heider & Farhad Rezvani & Herbert Matschinger & Jörg Dirmaier & Martin Härter & Lutz Herbarth & Patrick Steinisch & Hannes Böbinger & Franziska Schuhmann & Gundula Krack & Thomas Korth & Lara Thomsen & Daniela Patricia Chase & Robert Schreiber & Mark-Dominik Alscher & Benjamin Finger & Hans-Helmut König - 631-639 Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling
by Nicolas Boespflug & Jérôme Wittwer & Antoine Bénard - 641-653 Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
by Jean-Baptiste Trouiller & Georgios F. Nikolaidis & Bérengère Macabeo & Nicolas Meyer & Laetitia Gerlier & Max Schlueter & Philippe Laramee - 655-669 Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK
by Chelsea Chunwen Xiao & Nikita Makarchev & Xin Tao - 671-688 Disclosing the ‘Big C’: what does cancer survivorship signal to employers?
by Philippe Sterkens & Adelina Sharipova & Stijn Baert - 689-699 Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
by Jeroen H. J. Paulissen & Ahmed H. Seddik & Kyle J. Dunton & Christopher J. Livings & Marinus Hulst & Maarten J. Postma & Lisa A. Jong & Roel D. Freriks - 701-715 Immigrant assimilation in health care utilisation in Spain
by Zuleika Ferre & Patricia Triunfo & José-Ignacio Antón - 717-730 Using machine learning to estimate health spillover effects
by Bruno Wichmann & Roberta Moreira Wichmann
April 2024, Volume 25, Issue 3
- 363-377 Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada
by Michael Hong & Rose Anne Devlin & Gregory S. Zaric & Amardeep Thind & Sisira Sarma - 379-396 Heteroscedasticity of residual spending after risk equalization: a potential source of selection incentives in health insurance markets with premium regulation
by Michel Oskam & Richard C. van Kleef & Rudy Douven - 397-409 Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis
by Michael Situ & Ute I. Schwarz & Guangyong Zou & Eric McArthur & Richard B. Kim & Amit X. Garg & Sisira Sarma - 411-422 A cost-of-illness study of Behçet syndrome in Italy
by Valentina Lorenzoni & Diana Marinello & Ilaria Palla & Marta Mosca & Giuseppe Turchetti & Rosaria Talarico - 423-446 Self-interest, positional concerns and distributional considerations in healthcare preferences
by Aemiro Melkamu Daniel & Job Exel & Caspar G. Chorus - 447-457 Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial
by Didier Tchétché & Coline Dubois Gennes & Quentin Cormerais & Benjamin P. Geisler & Camille Dutot & Fanny Wilquin-Bequet & Manon Breau-Brunel & Béranger Lueza & Jan B. Pietzsch - 459-470 Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
by Munenobu Kashiwa - 471-496 Analyzing nurses’ decisions to leave their profession—a duration analysis
by Martin Kroczek - 497-511 Informal care at old age at home and in nursing homes: determinants and economic value
by Quitterie Roquebert & Marianne Tenand - 513-523 Excess healthcare expenditure in adults treated for solid cancer in childhood: a cohort study in France
by Daniel Bejarano-Quisoboni & Henri Panjo & Brice Fresneau & Chiraz El‑Fayech & François Doz & Aurore Surun & Florent Vathaire & Nathalie Pelletier-Fleury - 525-537 The link between physician motivation and care
by Anne Sophie Oxholm & Dorte Gyrd-Hansen & Christian Bøtcher Jacobsen & Ulrich Thy Jensen & Line Bjørnskov Pedersen - 539-548 Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease
by Isa Maria Steiner & Bernd Bokemeyer & Tom Stargardt
March 2024, Volume 25, Issue 2
- 189-192 Modeling European health systems: an ideal chain of services
by Livio Garattini & Marco Badinella Martini - 193-206 The causal effect of catastrophic health expenditure on poverty in Poland
by Aleksandra Kolasa & Ewa Weychert - 207-220 Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry
by Miao Guo & Lei Guo & Yang Li - 221-236 Pay-for-performance programs effectiveness in healthcare: the case of the end-stage renal disease quality incentive program
by Saeed Piri - 237-255 Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales
by Kent Matthews & Saeed Heravi & Peter Morgan & Nicholas Page & Jonathan Shepherd & Vaseekaran Sivarajasingam - 257-267 Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement
by P. Nieto-Gómez & C. Castaño-Amores & A. Rodríguez-Delgado & R. Álvarez-Sánchez - 269-279 Effect of comorbidities on healthcare expenditures for patients on kidney replacement therapy considering the treatment modality and duration in a French cohort
by Isabella Vanorio-Vega & Panayotis Constantinou & Victor Bret & Stéphanie Gentile & Patrik Finne & Bénédicte Sautenet & Philippe Tuppin & Cécile Couchoud - 281-292 Health impact of borders: general reflections and a case study from the Polish–German border
by Julia Kuntosch & Marie-Luise Ruebsam & Jakub Orsson & Dorota Orsson & Klaus Hahnenkamp & Jörg Hartleib & Steffen Flessa - 293-305 Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial
by Martin Emmert & Anja Schindler & Laura Heppe & Uwe Sander & Christiane Patzelt & Michael Lauerer & Eckhard Nagel & Cornelia Frömke & Oliver Schöffski & Cordula Drach - 307-317 Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma
by Béranger Lueza & Anne Aupérin & Charlotte Rigaud & Thomas G. Gross & Marta Pillon & Rafael F. Delgado & Anne Uyttebroeck & G. A. Amos Burke & József Zsíros & Monika Csóka & Mathieu Simonin & Catherine Patte & Véronique Minard-Colin & Julia Bonastre - 319-332 Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study
by Elizabeth M. Camacho & Gemma E. Shields & Carolyn A. Chew-Graham & Emily Eisner & Simon Gilbody & Elizabeth Littlewood & Dean McMillan & Kylie Watson & Pasco Fearon & Deborah J. Sharp - 333-361 Education and medication use later in life and the role of intelligence
by Gianmaria Niccodemi & Govert Bijwaard
February 2024, Volume 25, Issue 1
- 1-5 Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality
by Maurizio Capuozzo & Venere Celotto & Andrea Zovi & Roberto Langella & Francesco Ferrara - 7-19 Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population
by Shitong Xie & Jing Wu & Gang Chen - 21-30 Health-related quality of life assessed by EQ-5D-5L and its determinants among rural adults: result from the Henan rural cohort study
by Shengxiang Sang & Wei Liao & Ning Kang & Xueyan Wu & Ze Hu & Xiaotian Liu & Hongjian Zhang & Chongjian Wang - 31-47 The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions
by Alvaro Almeida - 49-76 The role of education in health policy reform outcomes: evidence from Japan
by Masato Oikawa - 77-89 Does a free maternity policy in Kenya work? Impact and cost–benefit consideration based on demographic health survey data
by Boniface Oyugi & Olena Nizalova & Sally Kendall & Stephen Peckham - 91-101 Risk, time preferences, trustworthiness and COVID-19 preventive behavior: evidence from France
by Julien Bergeot & Florence Jusot - 103-115 Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy
by Richard Huan Xu & Yi Dai & Shamay S. M. Ng & Hector W. H. Tsang & Shuyang Zhang & Dong Dong - 117-145 COVID-19 and EQ-5D-5L health state valuation
by Edward J. D. Webb & Paul Kind & David Meads & Adam Martin - 147-155 Canada population norms for the EQ-5D-5L
by Jiajun Yan & Shitong Xie & Jeffrey A. Johnson & Eleanor Pullenayegum & Arto Ohinmaa & Stirling Bryan & Feng Xie - 157-176 Short- and intermediate-term impact of DTC telemedicine consultations on subsequent healthcare consumption
by Cecilia Dahlgren & Emma Spånberg & Sofia Sveréus & Margareta Dackehag & Per Wändell & Clas Rehnberg - 177-185 Cost-effectiveness analysis of (accelerated) pre-operative versus (conventional) post-operative radiotherapy for patients with oral cavity cancer in Sweden
by Maria Silfverschiöld & Kristin Carlwig & Johan Jarl & Lennart Greiff & Per Nilsson & Johan Wennerberg & Björn Zackrisson & Ellinor Östensson & Johanna Sjövall - 187-187 Correction: Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemic
by Sebastian Himmler & Job Exel & Werner Brouwer & Sebastian Neumann-Böhme & Iryna Sabat & Jonas Schreyögg & Tom Stargardt & Pedro Pita Barros & Aleksandra Torbica
December 2023, Volume 24, Issue 9
- 1411-1420 EQ-5D-5L Portuguese population norms
by Pedro L. Ferreira & Luís N. Pereira & Patrícia Antunes & Lara N. Ferreira - 1421-1428 Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study
by Aino Vesikansa & Olli Halminen & Juha Mehtälä & Iiris Hörhammer & Teija Mikkola & Tero Ylisaukko-oja & Miika Linna - 1429-1440 Public preferences for policies promoting a healthy diet: a discrete choice experiment
by C. M. Dieteren & I. Bonfrer & W. B. F. Brouwer & J. Exel - 1441-1454 A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
by Ali Tafazzoli & Odette S. Reifsnider & Leana Bellanca & Jack Ishak & Marc Carrasco & Pal Rakonczai & Matthew Stargardter & Stephan Linden - 1455-1472 Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
by S. W. Quist & A. J. Postma & K. J. Myrén & L. A. Jong & M. J. Postma - 1473-1504 Prescription opioids and economic hardship in France
by Ilaria Natali & Mathias Dewatripont & Victor Ginsburgh & Michel Goldman & Patrick Legros - 1505-1515 Identifying factors associated with high use of acute care in Canada: a population-based retrospective study
by Mengmeng Zhang & Jinhui Ma & Feng Xie & Lehana Thabane - 1517-1530 Population norms in France with EQ-5D-5L: health states, value indexes, and VAS
by Laurène Gautier & Jessica Azzi & Grèce Saba & Geneviève Bonnelye & Gérard Pouvourville - 1531-1543 The social value of gambling: surplus estimates by gambling types for France
by Maxence Miéra & Sophie Massin & Vincent Eroukmanoff - 1545-1559 Cost and cost-effectiveness of four different SARS-CoV-2 active surveillance strategies: evidence from a randomised control trial in Germany
by Hoa Thi Nguyen & Claudia M. Denkinger & Stephan Brenner & Lisa Koeppel & Lucia Brugnara & Robin Burk & Michael Knop & Till Bärnighausen & Andreas Deckert & Manuela De Allegri - 1561-1573 Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data
by Alisa Stöber & Pavo Marijic & Christoph Kurz & Larissa Schwarzkopf & Florian Kirsch & Anja Schramm & Reiner Leidl - 1575-1586 Driving time drives the hospital choice: choice models for pelvic organ prolapse surgery in Italy
by Amerigo Ferrari & Chiara Seghieri & Andrea Giannini & Paolo Mannella & Tommaso Simoncini & Milena Vainieri
November 2023, Volume 24, Issue 8
- 1249-1252 Modeling European health systems: a theoretical exercise
by L. Garattini & Marco Badinella Martini - 1253-1270 To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study
by Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans - 1271-1283 The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis
by L. M. Peña-Longobardo & J. Oliva-Moreno & C. Fernández-Rodriguez - 1285-1296 Developing an Australian utility value set for the Early Childhood Oral Health Impact Scale-4D (ECOHIS-4D) using a discrete choice experiment
by Ruvini M. Hettiarachchi & Peter Arrow & Sameera Senanayake & Hannah Carter & David Brain & Richard Norman & Utsana Tonmukayawul & Lisa Jamieson & Sanjeewa Kularatna - 1297-1307 Assessment of health-related quality of life in individuals with depressive symptoms: validity and responsiveness of the EQ-5D-3L and the SF-6D
by Maike Stolz & Christian Albus & Manfred E. Beutel & Hans-Christian Deter & Kurt Fritzsche & Christoph Herrmann-Lingen & Matthias Michal & Katja Petrowski & Joram Ronel & Jobst-Hendrik Schultz & Wolfgang Söllner & Cora Weber & Martina Zwaan & Christian Krauth - 1309-1319 Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018
by Roberto Lillini & Francesco De Lorenzo & Paolo Baili & Elisabetta Iannelli & Laura M. Del Campo & Dina Pero & Gianfranca Traclò & Alessandro Sproviero & Milena Sant & Francesco Perrone - 1321-1341 Social costs of obesity in the Czech Republic
by Petra Landovská & Martina Karbanová - 1343-1355 Cost–benefit analysis of the CoCare intervention to improve medical care in long-term care nursing homes: an analysis based on claims data
by Boris A. Brühmann & Klaus Kaier & Rieka Warth & Erik Farin-Glattacker - 1357-1371 Excess costs of multiple sclerosis: a register-based study in Sweden
by Chantelle Murley & Petter Tinghög & Fitsum Sebsibe Teni & Alejandra Machado & Kristina Alexanderson & Jan Hillert & Korinna Karampampa & Emilie Friberg - 1373-1382 Significant healthcare burden and life cost of spinal muscular atrophy: real-world data
by Sophelia H. S. Chan & Carlos K. H. Wong & Tingting Wu & Wilfred Wong & Michael K. L. Yu & Ivan C. H. Au & Godfrey C. F. Chan - 1383-1397 Insurance coverage, long-term care utilization, and health outcomes
by Masaki Takahashi - 1399-1410 EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy
by Richard Huan Xu & Ming Lu & Shuyang Zhang & Dong Dong
September 2023, Volume 24, Issue 7
- 1019-1021 Competition and collaboration in health care: reconciling the irreconcilable? Lessons from The Netherlands
by Marco Varkevisser & Frédérique Franken & Stéphanie Geest & Erik Schut - 1023-1031 Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
by Olina Efthymiadou - 1033-1045 The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease
by Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Espín & Carlotta Sacerdote & Catarina Schiborn & Giovanna Masala & Sandra M. Colorado-Yohar & Lois Kim & Karel G. M. Moons & Gunnar Engström & Matthias B. Schulze & Léa Bresson & Concepción Moreno-Iribas & David Epstein - 1047-1060 Estimating healthcare expenditures after becoming divorced or widowed using propensity score matching
by Iris Meulman & Bette Loef & Niek Stadhouders & Tron Anders Moger & Albert Wong & Johan J. Polder & Ellen Uiters - 1061-1072 Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy
by India Flint & Jasmina Medjedovic & Ewa Drogon O’Flaherty & Elena Alvarez-Baron & Karthinathan Thangavelu & Natasa Savic & Aurelie Meunier & Louise Longworth - 1073-1083 Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries
by Przemysław Holko & Paweł Kawalec & Magdalena Sajak-Szczerba & Luisa Avedano & Małgorzata Mossakowska - 1085-1100 Do not PIMP my nursing home ride! The impact of Potentially Inappropriate Medications Prescribing on residents’ emergency care use
by Thomas Rapp & Jonathan Sicsic & Neda Tavassoli & Yves Rolland - 1101-1120 The effects of an increase in the retirement age on health care costs: evidence from administrative data
by Johannes Geyer & Mara Barschkett & Peter Haan & Anna Hammerschmid - 1121-1139 The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
by Ingrid A. Cox & Barbara Graaff & Hasnat Ahmed & Julie Campbell & Petr Otahal & Tamera J. Corte & Yuben Moodley & Nicole Goh & Peter Hopkins & Sacha Macansh & E. Haydn Walters & Andrew J. Palmer - 1141-1150 Can drones save lives and money? An economic evaluation of airborne delivery of automated external defibrillators
by Johann W. A. Röper & Katharina Fischer & Mina Carolina Baumgarten & Karl Christian Thies & Klaus Hahnenkamp & Steffen Fleßa - 1151-1216 The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review
by Michela Meregaglia & Elena Nicod & Michael Drummond - 1217-1233 What if 0 is not equal to 0? Inter-personal health utilities anchoring using the largest health gains
by Michał Jakubczyk - 1235-1237 “COVID-19 and income inequality in OECD countries:” A methodological comment
by Oded Stark - 1239-1241 COVID-19 and income inequality in OECD countries: a methodological comment—a reply
by John Wildman - 1243-1244 Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
by Afschin Gandjour - 1245-1248 Does health technology assessment compromise access to pharmaceuticals?
by Melanie Büssgen & Tom Stargardt
August 2023, Volume 24, Issue 6
- 853-865 Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy
by Lars Børty & Rasmus F. Brøndum & Heidi S. Christensen & Charles Vesteghem & Marianne Severinsen & Søren P. Johnsen & Lars H. Ehlers & Ursula Falkmer & Laurids Ø. Poulsen & Martin Bøgsted